Results 21 to 30 of about 60,441 (347)

The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State

Addiction Science & Clinical Practice, 2022
Background Opioid use disorder (OUD) is a serious health condition that is effectively treated with buprenorphine. However, only a minority of people with OUD are able to access buprenorphine.
Caleb J. Banta-Green, Mandy D. Owens, Jason R. Williams, Jeanne M. Sears, Anthony S. Floyd, Wendy Williams-Gilbert, Susan Kingston   +6 more
doaj   +1 more source

Discordance in Addressing Opioid Crisis in Rural Communities: Patient and Provider Perspectives

Pharmacy, 2022
Providing patient-centered care to manage chronic pain and opioid use disorder (OUD) is associated with improved health outcomes. However, adopting a holistic approach to providing care is often challenging in rural communities.
Bonyan Qudah, Martha A. Maurer, David A. Mott, Michelle A. Chui   +3 more
doaj   +1 more source

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)

Annals of Medicine, 2023
Introduction Treatment for opioid use disorder (OUD) with diacetylmorphine is an evidence-based form of drug treatment, but it is not available in the United States (US).
Sean T. Allen, Kristin E. Schneider, Saba Rouhani, Rebecca Hamilton White, Miles Morris, Jill Owczarzak, Susan G. Sherman   +6 more
doaj   +1 more source

The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study. [PDF]

, 2020
Background and aimsDespite the high prevalence of substance use among people in the US criminal justice system, little is known about the incidence of overdose mortality by use patterns, drug convictions and supervision setting.
Anderson R. N., Aos S., Bronson J., Center for Substance Abuse Treatment, Kaeble D., Kaeble D., Michigan Judicial Institute, National Center for Health Statistics, Zeng Z.   +8 more
core   +2 more sources

Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown

Addiction Science & Clinical Practice, 2022
Background Morbidity and mortality related to opioid use disorder (OUD) in the U.S. is at an all-time high. Innovative approaches are needed to address gaps in retention in treatment with medications for opioid use disorder (MOUD). Mobile health (mHealth)
Jacqueline Hodges, Marika Waselewski, William Harrington, Taylor Franklin, Kelly Schorling, Jacqueline Huynh, Alexa Tabackman, Kori Otero, Karen Ingersoll, Nassima Ait-Daoud Tiouririne, Tabor Flickinger, Rebecca Dillingham   +11 more
doaj   +1 more source

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone [PDF]

Mental Health Clinician, 2021
Introduction: Physician-pharmacist collaborative practice models (PPCPM) decrease barriers and increase access to medications for opioid use disorder (MOUD) but are not routine in practice. The purpose of this quality improvement initiative is to develop
Lindsay M. Mailloux, PharmD, Matthew T. Haas, PharmD, BCPP, BCPS, Janel M. Larew, PharmD, BCPS, Beth M. DeJongh, PharmD, BCPP, BCPS   +3 more
doaj   +1 more source

Incident and long-term opioid therapy among patients with psychiatric conditions and medications: a national study of commercial health care claims [PDF]

, 2017
There is growing evidence that opioid prescribing in the United States follows a pattern in which patients who are at the highest risk of adverse outcomes from opioids are more likely to receive long-term opioid therapy.
Bair, Matthew J., Chang, Zheng, D’Onofrio, Brian M., Gibbons, Robert D., Hur, Kwan, Krebs, Erin E., Kroenke, Kurt, Quinn, Patrick D., Rickert, Martin E., Scott, Eric L.   +9 more
core   +1 more source

Medications for management of opioid use disorder

American Journal of Health-System Pharmacy, 2019
Abstract Purpose The use of buprenorphine, methadone, and long-acting naltrexone for treatment of opioid use disorder (OUD) is discussed, including a review of current literature detailing treatment approaches and action steps to optimize treatment in acute care and office-based settings.
Jennifer L, Koehl, David E, Zimmerman, Patrick J, Bridgeman   +2 more
openaire   +2 more sources

Racial Differences in Medications for Opioid Use Disorder Initiation in a Carceral Setting. [PDF]

Subst Use Addctn J
Berk J, Brar J, Hoadley A, Martin R.
europepmc   +3 more sources

Buprenorphine added on brief cognitive behavioral therapy for treatment of methamphetamine use disorder [PDF]

, 2018
Background: Methamphetamine (MA) use remains a major public health concern around the world. Recent findings suggest that buprenorphine may be helpful for cocaine use reduction. Moreover, animal studies described reduced dopamine peak effect following MA
Dean AJ, Hassani-Abharian P, Hollister LE, Karimlou M, Kirchmayer U, Kosten TR, Mello NK, Nejati V, Raistrick D, Rothenberg JL,     +10 more
core   +1 more source